Chak V, Bybel M, Harne S, Kay JG, Wohlfert E, Balu-Iyer SV. Phosphatidylserine exposure on tolerogenic nanoparticle correlate with oral tolerance. Sci Rep. 2025 Dec 13. doi: 10.1038/s41598-025-32211-7. Epub ahead of print. PMID: 41390593.​

​

Chak V, Ovalle EJ, Bard J, Wohlfert EA, Kay JG, Balu-Iyer S. Single-cell transcriptional analysis of murine mesenteric lymph nodes following oral lyso-phosphatidylserine nanoparticle administration reveals cellular heterogeneity in tolerance features. J Pharm Sci. 2025 Sep;114(9):103919. doi: 10.1016/j.xphs.2025.103919. Epub 2025 Jul 23. PMID: 40712826.​

​

Nguyen NH, Chak V, Keller K, Wu H, Balu-Iyer SV. (2023) Phosphatidylserine-mediated oral tolerance. Cellular immunology (Feb), 384: 104660.​

​

Nguyen NH, Chen M, Chak V, Balu-Iyer SV. (2022) Biophysical Characterization of Tolerogenic Lipid-Based Nanoparticles Containing Phosphatidylcholine and Lysophosphatidylserine. Journal of pharmaceutical sciences (Jul), 111(7): 2072-2082.​

​

Bhatta M, Shenoy GN, Loyall JL, Gray BD, Bapardekar M, Conway A, Minderman H, Kelleher RJ, Carreno BM, Linette G, Shultz LD, Odunsi K, Balu-Iyer SV, Pak KY, Bankert RB. (2021) Novel phosphatidylserine-binding molecule enhances antitumor T-cell responses by targeting immunosuppressive exosomes in human tumor microenvironments. Journal for immunotherapy of cancer (Oct), 9(10). doi:10.1136/jitc-2021-003148​

​

Nguyen NH, Glassman FY, Dingman RK, Shenoy GN, Wohlfert EA, Kay JG, Bankert RB, Balu-Iyer SV. Rational design of a nanoparticle platform for oral prophylactic immunotherapy to prevent immunogenicity of therapeutic proteins. Sci Rep. 2021 Sep 8;11(1):17853. doi: 10.1038/s41598-021-97333-0. PMID: 34497305; PMCID: PMC8426360.​

​

Nguyen NH, Dingman RK, Balu-Iyer SV. Tolerogenic form of Factor VIII to prevent inhibitor development in the treatment of Hemophilia A. J Thromb Haemost. 2021 Nov;19(11):2744-2750. doi: 10.1111/jth.15497. Epub 2021 Sep 1. PMID: 34390536; PMCID: PMC8530911.​

​

Glassman FY, Balu-Iyer SV. Subcutaneous administration of Lyso-phosphatidylserine nanoparticles induces immunological tolerance towards Factor VIII in a Hemophilia A mouse model. Int J Pharm. 2018 Sep 5;548(1):642-648. doi: 10.1016/j.ijpharm.2018.07.018. Epub 2018 Jul 5. PMID: 29981412; PMCID: PMC6095657.​